<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62176">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02039336</url>
  </required_header>
  <id_info>
    <org_study_id>NL45985.031.13</org_study_id>
    <nct_id>NCT02039336</nct_id>
  </id_info>
  <brief_title>Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies</brief_title>
  <acronym>M13DAP</acronym>
  <official_title>Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Advanced KRAS Mutation Positive Colorectal, Non-small Cell Lung and Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Studies (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II multi-center open-label proof of concept study, consisting of two
      parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of
      the combination regimen of dacomitinib plus PD-0325901 in patients with advanced KRAS mutant
      (KRASm) colorectal cancer (CRC), non-small cell lung cancer (NSCLC), or pancreatic cancer.
      Part B is designed to perform a randomized comparison of the combination of dacomitinib and
      PD-0325901 versus standard of care therapy in patients with advanced KRASm CRC, NSCLC, or
      pancreatic cancer. It is hypothesized that with this combination strategy the progression
      free survival of patients with KRASm CRC, NSCLC or pancreatic cancer will be doubled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence rate of dose-limiting toxicities</measure>
    <time_frame>1.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dacomitinib: oral tablets PD-0325901: oral capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacomitinib</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-0325901</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological proof of advanced colorectal cancer (CRC), non-small cell
             lung cancer (NSCLC) or pancreatic cancer

          -  Written documentation of KRAS (exon 2, 3 or 4) mutation

          -  At least 18 years of age or older

          -  Able and willing to give written informed consent

          -  WHO performance status of 0, 1 or 2

        Exclusion Criteria:

          -  Symptomatic or untreated leptomeningeal disease

          -  Symptomatic brain metastasis

          -  Impairment of gastrointestinal function

          -  Uncontrolled infectious disease

          -  Left ventricular ejection fraction &lt; 50%

          -  Retinal degenerative disease or with history of uveitis, retinal vein occlusion or
             retinal detachment

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JHM Schellens, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FALM Eskens, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Centre Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MPJK Lolkema, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan HM Schellens, MD, PhD</last_name>
    <phone>0031205122446</phone>
    <email>j.slijkerman@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JHM Schellens, MD, PhD</last_name>
      <phone>+31 20 512 2446</phone>
      <email>j.slijkerman@nki.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
